{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:13:19Z","timestamp":1768997599583,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:sup>18<\/jats:sup>\n                    F-fluciclovine is a PET radiotracer approved for detection of recurrent prostate cancer, with utility in other malignancies being investigated. We present the case of a 71-year-old man with high-risk primary prostate cancer (Gleason score 9, prostate-specific antigen 34 ng\/mL) and newly diagnosed lung adenocarcinoma. As part of a clinical trial (NCT03081884), preoperative\n                    <jats:sup>18<\/jats:sup>\n                    F-fluciclovine PET\/CT showed localized abnormal uptake in the prostate gland with extracapsular extension. Additionally, an incidental anterior mediastinal mass measuring 2.2 \u00d7 1.8 cm demonstrated abnormal radiotracer uptake. Biopsy of the mediastinal mass confirmed invasive lung adenocarcinoma with solid and acinar patterns and high programmed death 1 ligand expression.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000003207","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T17:25:17Z","timestamp":1601486717000},"page":"e525-e527","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET\/CT in a Patient With Primary Prostate Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Olayinka A.","family":"Abiodun-Ojo","sequence":"first","affiliation":[{"name":"Radiology and Imaging Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinyemi A.","family":"Akintayo","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel L.","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Alemozaffar","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University School of Medicine, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"bib1-20260120","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00330-017-5213-1","article-title":"(18)F-fluciclovine PET\/MRI for preoperative lymph node staging in high-risk prostate cancer patients","volume":"28","year":"2018","journal-title":"Eur Radiol"},{"key":"bib2-20260120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","year":"2019","journal-title":"Lung Cancer"},{"key":"bib3-20260120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2967\/jnumed.117.204032","article-title":"Update on (18)F-fluciclovine PET for prostate cancer imaging","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib4-20260120","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.juro.2013.10.065","article-title":"Anti\u20133-[(18)F]FACBC positron emission tomography\u2013computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography\u2013computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial","volume":"191","year":"2014","journal-title":"J Urol"},{"key":"bib5-20260120","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-016-3383-8","article-title":"Recurrent prostate cancer detection with anti\u20133-[18F] FACBC PET\/CT: comparison with CT","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20260120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate cancer","volume":"197","year":"2017","journal-title":"J Urol"},{"key":"bib7-20260120","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2967\/jnumed.114.143628","article-title":"Anti\u20131-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib8-20260120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13550-019-0518-5","article-title":"Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and l-type amino acid transporter 1 (LAT1) in primary prostate cancer","volume":"9","year":"2019","journal-title":"EJNMMI Res"},{"key":"bib9-20260120","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2967\/jnumed.110.086074","article-title":"Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib10-20260120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3892\/mco.2012.54","article-title":"l-Type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer","volume":"1","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"bib11-20260120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.bjc.6604235","article-title":"Prognostic significance of l-type amino acid transporter 1 expression in resectable stage I\u2013III nonsmall cell lung cancer","volume":"98","year":"2008","journal-title":"Br J Cancer"},{"key":"bib12-20260120","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/bjc.2014.88","article-title":"ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non\u2013small cell lung cancer","volume":"110","year":"2014","journal-title":"Br J Cancer"},{"key":"bib13-20260120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11307-012-0606-7","article-title":"Pilot study of the utility of the synthetic PET amino-acid radiotracer anti\u20131-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions","volume":"15","year":"2013","journal-title":"Mol Imaging Biol"},{"key":"bib14-20260120","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/RLU.0000000000002781","article-title":"Differential 18F-FDG and 18F-fluciclovine uptake pattern in a patient with poorly differentiated adenocarcinoma of the lung and prostate cancer biochemical recurrence","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:00:41Z","timestamp":1768946441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003207","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}